22255-22-7
Chemical Structure
trans-Trimethoxyresveratrol
Synonym(s): trans-trismethoxy Resveratrol;(E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene
- CAS No.: 22255-22-7
- Formula:C17H18O3
- Molecular Weight:270.32
IUPAC Name: (E)-1,3-dimethoxy-5-(4-methoxystyryl)benzene
InChIKey: GDHNBPHYVRHYCC-SNAWJCMRSA-N
SMILES: COC1=CC=C(/C=C/C2=CC(OC)=CC(OC)=C2)C=C1
Biological Activity: Trans-Trimethoxyresveratrol (trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene) is an orally active natural derivative of Resveratrol (HY-16561). Trans-Trimethoxyresveratrol has an enhanced anticancer profile compared to Resveratrol, exhibiting higher potency than resveratrol, with improved cancer cell proliferation inhibition, induction of cell cycle arrest, decreased metastasis, and increased apoptosis. Trans-Trimethoxyresveratrol causes microtubule disassembling and tubulin depolymerization and exerts anti-angiogenic effects through VEGFR2. Trans-Trimethoxyresveratrol can be used for the studies of anti-angiogenic and anti-cancer (such as non-small cell lung cancer and osteosarcoma)[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
trans-Trimethoxyresveratrol | 99.35% | Trans-Trimethoxyresveratrol (trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene) is an orally active natural derivative of Resveratrol (HY-16561). Trans-Trimethoxyresveratrol has an enhanced anticancer profile compared to Resveratrol, exhibiting higher potency than resveratrol, with improved cancer cell proliferation inhibition, induction of cell cycle arrest, decreased metastasis, and increased apoptosis. Trans-Trimethoxyresveratrol causes microtubule disassembling and tubulin depolymerization and exerts anti-angiogenic effects through VEGFR2. Trans-Trimethoxyresveratrol can be used for the studies of anti-angiogenic and anti-cancer (such as non-small cell lung cancer and osteosarcoma). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Aldawsari FS, Velázquez-Martínez CA. 3,4',5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency. Invest New Drugs. 2015 Jun;33(3):775-86. [Content Brief]
- [2]. Belleri M,et al. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4'-trimethoxystilbene. Mol Pharmacol. 2005 May;67(5):1451-9. [Content Brief]
- [3]. Alex D, et al. Resveratrol derivative, trans-3,5,4'-trimethoxystilbene, exerts antiangiogenic and vascular-disrupting effects in zebrafish through the downregulation of VEGFR2 and cell-cycle modulation. J Cell Biochem. 2010 Feb 1;109(2):339-46. [Content Brief]
- [4]. Lu M, et al. Trans-3,5,4´-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498. J Cell Mol Med. 2019 Apr;23(4):2431-2441. [Content Brief]
- [5]. Lin HS, Ho PC. Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in sprague-dawley rats: the impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability. J Pharm Sci. 2011 Oct;100(10):4491-500. [Content Brief]
- [6]. Feng Y, et al. Resveratrol Derivative, Trans-3, 5, 4'-Trimethoxystilbene Sensitizes Osteosarcoma Cells to Apoptosis via ROS-Induced Caspases Activation. Oxid Med Cell Longev. 2021 Mar 25;2021:8840692. [Content Brief]
Keywords
